Yarrow Bioscience (YARW) Current Assets (2016 - 2026)

Yarrow Bioscience (YARW) has reported Current Assets for 11 consecutive years, with $23.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Current Assets fell 46.95% year-over-year to $23.5 million; the trailing twelve-month figure through Jun 2026 stood at $23.5 million (down 46.95% YoY), and the FY2025 full-year result was $30.0 million, down 53.43% from the prior year.
• Current Assets eased to $23.5 million in Q2 2026 per YARW's latest filing, from $25.8 million in the prior quarter.
• Across five years, Current Assets topped out at $96.0 million in Q4 2023 and bottomed at $17.5 million in Q3 2023.
• Historically, Current Assets has averaged $50.3 million across 5 years, with a median of $44.3 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Current Assets plunged 60.24% in 2023, then jumped 319.94% in 2024.
• Over 5 years, Current Assets stood at $38.3 million in 2022, then jumped by 150.72% to $96.0 million in 2023, then plunged by 32.85% to $64.4 million in 2024, then tumbled by 53.43% to $30.0 million in 2025, then retreated by 21.61% to $23.5 million in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $23.5 million, $25.8 million, and $30.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.